Novartis (NOVN) Q3 2025 earnings summary

Executive summary

• Achieved Q3 2025 net sales growth of 7% in constant currency (cc) and 8% in USD, with core operating income up 7% (cc), driven by strong performance from priority brands and new launches despite generic erosion.

• Net sales reached $13.9 billion in Q3 and $41.2 billion for the first nine months, with operating income up 24%-27% and net income up 23%-27% year-over-year.

• Significant pipeline milestones included FDA approvals (remibrutinib/Rhapsido) and positive Phase III data for ianalumab, Pluvicto, and Fabhalta.

• Reaffirmed full-year 2025 guidance for high single-digit net sales growth and low-teens core operating income growth, with the Avidity acquisition expected to enhance long-term prospects.

• Strategic acquisitions (Avidity, Tourmaline Bio, Anthos, Regulus) and share buybacks support long-term growth and shareholder returns.

Financial highlights

• Q3 net sales: $13.9B (+7% cc, +8% USD); nine months: $41.2B (+11% cc/USD); core operating income up 7% (cc), operating income up 24%-27%.

• Q3 core EPS: $2.25 (+10% cc, +9% USD); nine months: $6.94 (+21% cc, +19% USD); Q3 EPS: $2.04 (+29%-31%).

• Free cash flow: $6.2B in Q3 (+4%); $15.9B for nine months (+26%).

• Core margin for Q3: 39.3%; nine months: 41.2%.

• Net debt at September 30, 2025: $20.4B, up from $16.1B at year-end 2024.

Outlook and guidance

• Full-year 2025 guidance reaffirmed: high single-digit net sales growth, low-teens core operating income growth.

• Q4 2025 growth expected to be impacted by prior-year one-time items and generic erosion; 2026 expected to be a year of two halves.

• Currency impact for 2025 expected to be neutral to slightly positive for sales, negative for core margin.

• Avidity acquisition to cause 1%-2% margin dilution for three years, with a return to 40% margin by 2029.

• Core net financial expenses projected at ~$1.1B; core tax rate expected at 16-16.5%.